Rigel Pharmaceuticals (RIGL) Return on Invested Capital (2021 - 2026)

Rigel Pharmaceuticals has reported Return on Invested Capital for 5 years, with the latest figure at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Invested Capital fell 1.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (down 1.0% YoY), and the FY2025 full-year result was 0.02%, up 6.0% from the prior year.
• Return on Invested Capital for Q1 2026 stood at 0.01%, down from 0.01% in the prior quarter.
• The five-year high for Return on Invested Capital was 0.07% in Q3 2022, with the low at 0.51% in Q2 2022.
• Average Return on Invested Capital over 4 years is 0.06%, with a median of 0.01% recorded in 2025.
• Year-over-year, Return on Invested Capital tumbled 51 bps in 2022 and gained 13 bps in 2025.
• Tracing RIGL's Return on Invested Capital over 4 years: stood at 0.07% in 2022, then slumped by 268 bps to 0.11% in 2024, then soared by 112 bps to 0.01% in 2025, then plunged by 34 bps to 0.01% in 2026.
• The last three Return on Invested Capital figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.

Peer Comparison